The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs
- PMID: 20807189
- DOI: 10.2174/157016111795495503
The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs
Abstract
Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.
Similar articles
-
Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.Curr Vasc Pharmacol. 2012 Jul;10(4):479-93. doi: 10.2174/157016112800812836. Curr Vasc Pharmacol. 2012. PMID: 22272903 Review.
-
Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.Cardiovasc Hematol Agents Med Chem. 2017;15(1):3-16. doi: 10.2174/1871525715666170127101605. Cardiovasc Hematol Agents Med Chem. 2017. PMID: 28137223 Review.
-
[VEGF, anti-vEGF and diseases].Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2. Bull Acad Natl Med. 2008. PMID: 18819684 Review. French.
-
Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.Drug Discov Today. 2011 Dec;16(23-24):1052-60. doi: 10.1016/j.drudis.2011.08.007. Epub 2011 Aug 22. Drug Discov Today. 2011. PMID: 21875682 Review.
-
Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. doi: 10.2174/157489207779561426. Recent Pat Anticancer Drug Discov. 2007. PMID: 18221053 Review.
Cited by
-
Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease.Kidney Int. 2014 Apr;85(4):833-44. doi: 10.1038/ki.2013.477. Epub 2013 Dec 18. Kidney Int. 2014. PMID: 24352153 Free PMC article.
-
Vascular endothelial growth factor from embryonic status to cardiovascular pathology.Rep Biochem Mol Biol. 2014 Apr;2(2):59-69. Rep Biochem Mol Biol. 2014. PMID: 26989723 Free PMC article. Review.
-
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.Health Technol Assess. 2020 Jan;24(2):1-180. doi: 10.3310/hta24020. Health Technol Assess. 2020. PMID: 31931920 Free PMC article.
-
Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling.Neuropharmacology. 2012 Sep;63(4):642-52. doi: 10.1016/j.neuropharm.2012.04.033. Epub 2012 May 10. Neuropharmacology. 2012. PMID: 22580375 Free PMC article.
-
The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention.J Cancer Prev. 2016 Mar;21(1):1-12. doi: 10.15430/JCP.2016.21.1.1. Epub 2016 Mar 30. J Cancer Prev. 2016. PMID: 27051643 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources